These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 24892422)

  • 41. IGIV-C, a novel intravenous immunoglobulin: evaluation of safety, efficacy, mechanisms of action, and impact on quality of life.
    Bussel JB; Eldor A; Kelton JG; Varon D; Brenner B; Gillis S; Angiolillo A; Kulkarni R; Abshire TC; Kelleher J;
    Thromb Haemost; 2004 Apr; 91(4):771-8. PubMed ID: 15045139
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy and Safety of Anti-D Immunoglobulins versus Intravenous Immunoglobulins for Immune Thrombocytopenia in Children: Systematic Review and Meta-analysis of Randomized Controlled Trials.
    Lioger B; Maillot F; Ternant D; Passot C; Paintaud G; Bejan-Angoulvant T
    J Pediatr; 2019 Jan; 204():225-233.e8. PubMed ID: 30314658
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Randomized trial comparing intravenous immunoglobulin with methylprednisolone pulse therapy in acute idiopathic thrombocytopenic purpura. Danish I.T.P. Study Group.
    Rosthøj S; Nielsen S; Pedersen FK
    Acta Paediatr; 1996 Aug; 85(8):910-5. PubMed ID: 8863869
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Treatment of adult chronic autoimmune thrombocytopenic purpura with repeated high-dose intravenous immunoglobulin.
    Godeau B; Lesage S; Divine M; Wirquin V; Farcet JP; Bierling P
    Blood; 1993 Sep; 82(5):1415-21. PubMed ID: 8364194
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dexamethasone plus oseltamivir versus dexamethasone in treatment-naive primary immune thrombocytopenia: a multicentre, randomised, open-label, phase 2 trial.
    Sun L; Wang J; Shao L; Yuan C; Zhao H; Li D; Wang Z; Han P; Yu Y; Xu M; Zhao H; Qiu J; Zhou H; Liu X; Hou Y; Peng J; Hou M
    Lancet Haematol; 2021 Apr; 8(4):e289-e298. PubMed ID: 33770484
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Intravenous immunoglobulin vs observation in childhood immune thrombocytopenia: a randomized controlled trial.
    Heitink-Pollé KMJ; Uiterwaal CSPM; Porcelijn L; Tamminga RYJ; Smiers FJ; van Woerden NL; Wesseling J; Vidarsson G; Laarhoven AG; de Haas M; Bruin MCA;
    Blood; 2018 Aug; 132(9):883-891. PubMed ID: 29945954
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Different dosages of intravenous immunoglobulin (IVIg) in treating immune thrombocytopenia with long-term follow-up of three years: Results of a prospective study including 167 cases.
    Zhou Z; Qiao Z; Li H; Luo N; Zhang X; Xue F; Yang R
    Autoimmunity; 2016; 49(1):50-7. PubMed ID: 26525513
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Assessment of the efficacy of a last-generation polyvalent immunoglobulin in the treatment of idiopathic thrombocytopenic purpura.
    Pacetti P; Garau D; Caramatti C; Mangoni L; Zamboni V; Canova N; Rizzoli V
    Curr Med Res Opin; 1997; 13(9):517-27. PubMed ID: 9169254
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Randomized trial of high-dose methylprednisolone versus intravenous immunoglobulin for the treatment of acute idiopathic thrombocytopenic purpura in children.
    Ancona KG; Parker RI; Atlas MP; Prakash D
    J Pediatr Hematol Oncol; 2002 Oct; 24(7):540-4. PubMed ID: 12368690
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Intravenous immunoglobulin and autoimmune thrombocytopenic purpura: 22 years on.
    Bierling P; Godeau B
    Vox Sang; 2004 Jan; 86(1):8-14. PubMed ID: 14984554
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Intravenous immunoglobulin or high-dose methylprednisolone, with or without oral prednisone, for adults with untreated severe autoimmune thrombocytopenic purpura: a randomised, multicentre trial.
    Godeau B; Chevret S; Varet B; Lefrère F; Zini JM; Bassompierre F; Chèze S; Legouffe E; Hulin C; Grange MJ; Fain O; Bierling P;
    Lancet; 2002 Jan; 359(9300):23-9. PubMed ID: 11809183
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Treatment of immune thrombocytopenic purpura in Pediatrics. Therapeutic efficacy of a regional intravenous immunoglobulin G].
    Buteler C; Colombo H; Gabosi G; Manfredi MJ; Montero S; Pasquali MA; Rougier C; Sisti AM
    Medicina (B Aires); 2001; 61(5 Pt 1):522-8. PubMed ID: 11721317
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Predictive factors of response to IVIG in pediatric immune thrombocytopenic purpura.
    Higashide Y; Hori T; Yoto Y; Kabutoya H; Honjo S; Sakai Y; Nojima M; Yoda M; Yamamoto M; Tsutsumi H
    Pediatr Int; 2018 Apr; 60(4):357-361. PubMed ID: 29297955
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Safety and efficacy of a 10% intravenous immunoglobulin preparation in patients with immune thrombocytopenic purpura: results of two international, multicenter studies.
    Kovaleva L; Apte S; Damodar S; Ramanan V; Loriya S; Navarro-Puerto J; Khojasteh A;
    Immunotherapy; 2016 Dec; 8(12):1371-1381. PubMed ID: 27817251
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparison of intravenous immune globulin and high dose anti-D immune globulin as initial therapy for childhood immune thrombocytopenic purpura.
    Kane I; Ragucci D; Shatat IF; Bussel J; Kalpatthi R
    Br J Haematol; 2010 Apr; 149(1):79-83. PubMed ID: 20096011
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A prospective, randomized trial of conventional, dose-accelerated corticosteroids and intravenous immunoglobulin in children with newly diagnosed idiopathic thrombocytopenic purpura.
    Fujisawa K; Iyori H; Ohkawa H; Konishi S; Bessho F; Shirahata A; Miyazaki S; Akatsuka J;
    Int J Hematol; 2000 Oct; 72(3):376-83. PubMed ID: 11185998
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Safety and tolerability of a novel chromatography-based intravenous immunoglobulin when administered at a high infusion rate in patients with immune thrombocytopenic purpura.
    Bussel JB; Hanna K;
    Am J Hematol; 2007 Mar; 82(3):192-8. PubMed ID: 17109385
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Standard-dose intravenous anti-D immunoglobulin versus intravenous immunoglobulin in the treatment of newly diagnosed childhood primary immune thrombocytopenia.
    Papagianni A; Economou M; Tragiannidis A; Karatza E; Tsatra I; Gombakis N; Athanassiadou-Piperopoulou F; Athanasiou-Metaxa M
    J Pediatr Hematol Oncol; 2011 May; 33(4):265-9. PubMed ID: 21516022
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Retrospective analysis of rituximab therapy and splenectomy in childhood chronic and refractory immune thrombocytopenic purpura.
    Ay Y; Karapinar TH; Oymak Y; Toret E; Demirag B; Ince D; Ozcan E; Moueminoglou N; Koker SA; Vergin C
    Blood Coagul Fibrinolysis; 2016 Jun; 27(4):431-5. PubMed ID: 26656905
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A randomized multicenter study: safety and efficacy of mini-pool intravenous immunoglobulin versus standard immunoglobulin in children aged 1-18 years with immune thrombocytopenia.
    Elalfy M; Reda M; Elghamry I; Elalfy O; Meabed M; El-Ekiaby N; El-Hawy MA; Goubran H; El-Ekiaby M
    Transfusion; 2017 Dec; 57(12):3019-3025. PubMed ID: 28880361
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.